Oncotarget

Research Papers:

Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier

David J. Eve, George Steiner, Ajay Mahendrasah, Paul R. Sanberg, Crupa Kurien, Avery Thomson, Cesar V. Borlongan and Svitlana Garbuzova-Davis _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:10621-10634. https://doi.org/10.18632/oncotarget.24360

Metrics: PDF 824 views  |   HTML 1367 views  |   ?  


Abstract

David J. Eve1,2, George Steiner1, Ajay Mahendrasah1, Paul R. Sanberg1,2,3,4, Crupa Kurien1, Avery Thomson1, Cesar V. Borlongan1,2 and Svitlana Garbuzova-Davis1,2,3,5

1Center of Excellence for Aging and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

2Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

3Department of Pathology and Cell Biology, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

4Department of Psychiatry, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

5Department of Molecular Pharmacology and Physiology, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

Correspondence to:

Svitlana Garbuzova-Davis, email: sgarbuzo@health.usf.edu

Keywords: amyotrophic lateral sclerosis; symptomatic ALS mice; microhemorrhage; human bone marrow CD34+ cells; blood-spinal cord barrier

Received: September 24, 2017    Accepted: January 20, 2018    Published: January 31, 2018

ABSTRACT

Blood-spinal cord barrier (BSCB) alterations, including capillary rupture, have been demonstrated in animal models of amyotrophic lateral sclerosis (ALS) and ALS patients. To date, treatment to restore BSCB in ALS is underexplored. Here, we evaluated whether intravenous transplantation of human bone marrow CD34+ (hBM34+) cells into symptomatic ALS mice leads to restoration of capillary integrity in the spinal cord as determined by detection of microhemorrhages. Three different doses of hBM34+ cells (5 × 104, 5 × 105 or 1 × 106) or media were intravenously injected into symptomatic G93A SOD1 mice at 13 weeks of age. Microhemorrhages were determined in the cervical and lumbar spinal cords of mice at 4 weeks post-treatment, as revealed by Perls’ Prussian blue staining for ferric iron. Numerous microhemorrhages were observed in the gray and white matter of the spinal cords in media-treated mice, with a greater number of capillary ruptures within the ventral horn of both segments. In cell-treated mice, microhemorrhage numbers in the cervical and lumbar spinal cords were inversely related to administered cell doses. In particular, the pervasive microvascular ruptures determined in the spinal cords in late symptomatic ALS mice were significantly decreased by the highest cell dose, suggestive of BSCB repair by grafted hBM34+ cells. The study results provide translational outcomes supporting transplantation of hBM34+ cells at an optimal dose as a potential therapeutic strategy for BSCB repair in ALS patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24360